Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development

References

• Van Deventer SJH. Tumour necrosis factor and Crohn’s disease. Gut. 1997;40:443–448.
   PubMed Web of Science ®Google Scholar
• Brennan FM, Jackson A, Chantry D, et al. Inhibitory effect of TNFa antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;334:244–247.
   Google Scholar
• Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105–1110.
   PubMed Web of Science ®Google Scholar
• Van Dullemen HM, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129–135.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303–2311.
   PubMed Web of Science ®Google Scholar
• Kiesler P, Fuss IJ, Strober W. Experimental models of inflammatory bowel diseases. Med Hyg (Geneve). 2001;59:241–248.
   Google Scholar
• De Vries LCS, Ghiboub M, van Hamersveld PHP, et al. Tyrosine kinase 2 signalling drives pathogenic T cells in colitis. J Crohn’s Colitis. 2021;15:617–630.
   Google Scholar
• Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310–1316.
   PubMed Web of Science ®Google Scholar
• Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25:309–318.
   PubMed Web of Science ®Google Scholar
• Hesterberg PE, Hines DW, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996;1:1373–1380.
   Google Scholar
• Kato S, Hokari R, Matsuzaki K, et al. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther. 2000;295:183–189.
   PubMed Web of Science ®Google Scholar
• Picarella D, Hurlbut D, Rottman J, et al. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol. 1997;158:2099–2106.
   PubMed Web of Science ®Google Scholar
• Burns RC, Rivera-Nieves J, Moskaluk CA, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn’s disease in mice. Gastroenterology. 2001;121:1428–1436.
   PubMed Web of Science ®Google Scholar
• Soriano A, Salas A, Salas A, et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Investig. 2000;80:1541–1551.
   PubMed Web of Science ®Google Scholar
• Popp V, Gerlach K, Mott S, et al. Rectal delivery of a DNAzyme that specifically blocks the transcription factor GATA3 and reduces colitis in mice. Gastroenterology. 2017;152:176–192.e5.
   PubMed Web of Science ®Google Scholar
• Atreya R, Kühbacher T, Schmitt H, et al. DOP Session 7 : novel therapies Luminal application of a GATA3-specific DNAzyme ameliorates mucosal inflammation in a randomised trial with active ulcerative colitis patients DOP056 Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in:69–70.
   Google Scholar
• Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 2002;17:629–638.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Panés J, Khurana S, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015;64:894–900.
   PubMed Web of Science ®Google Scholar
• Danese S, Rudziński J, Brandt W, et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut. 2015;64:243–249.
   PubMed Web of Science ®Google Scholar
• Hong SN, Joung JG, Bae JS, et al. RNA-seq reveals transcriptomic differences in inflamed and noninflamed intestinal mucosa of Crohn’s disease patients compared with normal mucosa of healthy controls. Inflamm Bowel Dis. 2017;23:1098–1108.
   PubMed Web of Science ®Google Scholar
• Wu F, Dassopoulos T, Cope L, et al. Genome-wide gene expression differences in Crohn’s disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007;13:807–821.
   PubMed Web of Science ®Google Scholar
• Montero-Meléndez T, Llor X, García-Planella E, et al. Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling. PLoS One. 2013;8:1–9.
   Web of Science ®Google Scholar
• Planell N, Lozano JJ, Mora-Buch R, et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut. 2013;62:967–976.
   PubMed Web of Science ®Google Scholar
• Liu Q, Harpaz N. Expression profiling of inflammatory and immunological genes in collagenous colitis. J Crohn’s Colitis. 2019;13:764–771.
   Google Scholar
• Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612–1619.
   PubMed Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Lemaire K, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One. 2009;4(11):e7984.
   Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Machiels K, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol. 2011;106:748–761.
   PubMed Web of Science ®Google Scholar
• Visvanathan S, Baum P, Salas A, et al. Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn’s disease: results from a randomised phase II biopsy sub-study. J Crohn’s Colitis. 2018;12:1170–1179.
   Google Scholar
• Wang Y, Gao X, Zhang X, et al. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease. Gut Microbes. 2021;13:1–18.
   PubMed Web of Science ®Google Scholar
• Doherty MK, Ding T, Koumpouras C, et al. Fecal microbiota signatures are associated with response to ustekinumab therapy among crohn’s disease patients. MBio. 2018;9(2):e02120-17.
   Web of Science ®Google Scholar
• Ribaldone DG, Caviglia GP, Abdulle A, et al. Adalimumab therapy improves intestinal dysbiosis in Crohn’s disease. J Clin Med. 2019;8:1646.
   Web of Science ®Google Scholar
• Dovrolis N, Michalopoulos G, Theodoropoulos GE, et al. The interplay between mucosal microbiota composition and host gene-expression is linked with infliximab response in inflammatory bowel diseases. Microorganisms. 2020;8(3):438.
   Web of Science ®Google Scholar
• Planell N, Masamunt MC, Leal RF, et al. Usefulness of transcriptional blood biomarkers as a non-invasive surrogate marker of mucosal healing and endoscopic response in ulcerative colitis. J Crohn’s Colitis. 2017;11:1335–1346.
   Google Scholar
• Schreiber S, Aden K, Bernardes JP, et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. 2021;160:2354–2366.e11.
   PubMed Web of Science ®Google Scholar
• Bertani L, Caviglia GP, Antonioli L, et al. Serum interleukin-6 and −8 as predictors of response to vedolizumab in inflammatory bowel diseases. J Clin Med. 2020;9:1323.
   Web of Science ®Google Scholar
• Caviglia G, Rosso C, Stalla F, et al. On-treatment decrease of serum interleukin-6 as a predictor of clinical response to biologic therapy in patients with inflammatory bowel diseases. J Clin Med. 2020;9:800.
   PubMed Web of Science ®Google Scholar
• Kourkoulis P, Kapizioni C, Michalopoulos G, et al. Novel potential biomarkers for the diagnosis and monitoring of patients with ulcerative colitis. Eur J Gastroenterol Hepatol. 2019;31:1173–1183.
   PubMed Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Lemmens B, et al. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018;67:43–52.
   PubMed Web of Science ®Google Scholar
• Haberman Y, Karns R, Dexheimer PJ, et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019;10(1):38.
   Web of Science ®Google Scholar
• Aguilar D, Revilla L, Garrido-Trigo A, et al. Randomized controlled trial substudy of cell-specific mechanisms of janus kinase 1 inhibition with upadacitinib in the Crohn’s disease intestinal mucosa: analysis from the CELEST study. Inflamm Bowel Dis. 2021;1–11. DOI: https://doi.org/10.1093/ibd/izab116.
   Google Scholar
• Leal RF, Planell N, Kajekar R, et al. Identification of inflammatory mediators in patients with Crohn’s disease unresponsive to anti-TNFα therapy. Gut. 2015;64:233–242.
   PubMed Web of Science ®Google Scholar
• Tew GW, Hackney JA, Gibbons D, et al. Association between response to etrolizumab and expression of integrin αe and granzyme A in colon biopsies of patients with ulcerative colitis. Gastroenterology. 2016;150:477–487.e9.
   PubMed Web of Science ®Google Scholar
• Zhou H, Xi L, Ziemek D, et al. Molecular profiling of ulcerative colitis subjects from the TURANDOT trial reveals novel pharmacodynamic/efficacy biomarkers. J Crohn’s Colitis. 2019;13:702–713.
   Google Scholar
• Smillie C, Biton M, Ordovas-Montanes J, et al. Inter-cellular rewiring of the human colon during ulcerative colitis. Cell. 2019;178:714–730.
   PubMed Web of Science ®Google Scholar
• Kinchen J, Chen HH, Parikh K, et al. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. Cell. 2018;175:372–386.e17.
   PubMed Web of Science ®Google Scholar
• Corridoni D, Antanaviciute A, Gupta T, et al. Single-cell atlas of colonic CD8+ T cells in ulcerative colitis. Nat Med. Springer US. 2020;26(9):1480–1490.
   PubMed Web of Science ®Google Scholar
• Martin J, Boschetti G, Chang C, et al. Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy. bioRxiv. 2018;178:503102.
   Google Scholar
• Di Sabatino A, Rovedatti L, Kaur R, et al. Targeting gut T cell Ca 2+ release-activated Ca 2+ Channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. J Immunol. 2009;183:3454–3462.
   PubMed Web of Science ®Google Scholar
• Haile PA, Votta BJ, Marquis RW, et al. The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase. J Med Chem. 2016;59:4867–4880.
   PubMed Web of Science ®Google Scholar
• Haile PA, Casillas LN, Votta BJ, et al. Discovery of a first-in-class receptor interacting protein 2 (RIP2) kinase specific clinical candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate, for the treatment of inflammatory diseases. J Med Chem. 2019;62:6482–6494.
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D, Stamler JS, Bachwich D, et al. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. Gut. 1995;36:718–723.
   PubMed Web of Science ®Google Scholar
• Bassolas-Molina H, Raymond E, Labadia M, et al. An RORyt oral inhibitor modulates IL-17 responses in peripheral blood and intestinal mucosa of Crohn’s disease patients. Front Immunol. 2018;9:773–790.
   PubMed Web of Science ®Google Scholar
• Reisdorf WC, Xie Q, Zeng X, et al. Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease. PLoS One. 2019;;14(4):e0215033.
   PubMed Web of Science ®Google Scholar
• Monteleone I, Federici M, Sarra M, et al. Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. Gastroenterology. 2012;143:1277–1287.e4.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601–609.
   PubMed Web of Science ®Google Scholar
• Vossenkämper A, Hundsrucker C, Page K, et al. A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease. Gastroenterology. 2014;147:172–183.
   PubMed Web of Science ®Google Scholar
• Baba N, Van VQ, Wakahara K, et al. CD47 fusion protein targets CD172a+ cells in Crohn’s disease and dampens the production of IL-1β and TNF. J Exp Med. 2013;210:1251–1263.
   PubMed Web of Science ®Google Scholar
• Meijer MJ, Mieremet-Ooms MAC, Van Duijn W, et al. Effect of the anti-tumor necrosis factor-antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. 2006.
   Google Scholar
• Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261–1270.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Heinig T, Thiele HG, et al. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 1995;108:1434–1444.
   PubMed Web of Science ®Google Scholar
• Gordon JN, Prothero JD, Thornton CA, et al. CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease. J Crohn’s Colitis. 2009;3:175–182.
   Google Scholar
• Stallmach A, Marth T, Weiß B, et al. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo. Gut. 2004;53:339–345.
   PubMed Web of Science ®Google Scholar
• Schulz D, Zanotelli VRT, Fischer JR, et al. Simultaneous multiplexed imaging of mRNA and proteins with subcellular resolution in breast cancer tissue samples by mass cytometry. Cell Syst. 2018;6:25–36.e5.
   PubMed Web of Science ®Google Scholar
• Duckworth AD, Gherardini PF, Sykorova M, et al. Multiplexed profiling of RNA and protein expression signatures in individual cells using flow or mass cytometry. Nat Protoc. 2019;14:901–920.
   PubMed Web of Science ®Google Scholar
• Merritt CR, Ong GT, Church SE, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38:586–599.
   PubMed Web of Science ®Google Scholar
• Warren S Simultaneous, multiplexed detection of RNA and protein on the NanoString® nCounter® Platform. Springer Protocols; 2018.
   Google Scholar
• Dikshit A, Zong H, Anderson C, et al. Simultaneous visualization of RNA and protein expression in tissue using a combined RNAscopeTM in situ hybridization and immunofluorescence protocol. Situ Hybrid Protoc. 2020;2.
   Google Scholar
• Calenda G, Keawvichit R, Arrode-Brusés G, et al. Integrin α 4 β 7 blockade preferentially impacts CCR6 + lymphocyte subsets in blood and mucosal tissues of naive rhesus macaques. J Immunol. 2018;200:810–820.
   PubMed Web of Science ®Google Scholar
• Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012;18:2107–2119.
   PubMed Web of Science ®Google Scholar
• Wang C, Hanly EK, Wheeler LW, et al. Effect of α4β7 blockade on intestinal lymphocyte subsets and lymphoid tissue development. Inflamm Bowel Dis. 2010;16:1751–1762.
   PubMed Web of Science ®Google Scholar
• Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384:309–318.
   PubMed Web of Science ®Google Scholar
• Hassan-Zahraee M, Banerjee A, Cheng JB, et al. Anti-MAdCAM antibody increases β7+ T cells and CCR9 gene expression in the peripheral blood of patients with Crohn’s disease. J Crohn’s Colitis. 2018;12:77–86.
   Google Scholar
• Kosoy R, Kim-Schulze S, Rahman A, et al. Deep analysis of the peripheral immune system in IBD reveals new insight in disease subtyping and response to monotherapy or combination therapy. 2021;12:599–632.
   Google Scholar
• Veny M, Garrido-Trigo A, Corraliza AM, et al. Dissecting common and unique effects of anti-α4β7 and anti-tumor necrosis factor treatment in ulcerative colitis. J Crohn’s Colitis. 2021;15:441–452.
   Google Scholar
• Fuchs F, Schillinger D, Atreya R, et al. Clinical response to vedolizumab in ulcerative colitis patients is associated with changes in integrin expression profiles. Front Immunol. 2017;8:764.
   Web of Science ®Google Scholar
• Rath T, Billmeier U, Ferrazzi F, et al. Effects of anti-integrin treatment with vedolizumab on immune pathways and cytokines in inflammatory bowel diseases. Front Immunol. 2018;9:1700.
   PubMed Web of Science ®Google Scholar
• Jung P, Sato T, Merlos-Suárez A, et al. Isolation and in vitro expansion of human colonic stem cells. Nat Med. 2011;17:1225–1227.
   PubMed Web of Science ®Google Scholar
• McCracken KW, Howell JC, Wells JM, et al. Generating human intestinal tissue from pluripotent stem cells in vitro. Nat Protoc. 2011;6:1920–1928.
   PubMed Web of Science ®Google Scholar
• Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011;141:1762–1772.
   PubMed Web of Science ®Google Scholar
• Miyoshi H, Stappenbeck TS. In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture. Nat Protoc. 2013;8:2471–2482.
   PubMed Web of Science ®Google Scholar
• Wang Y, DiSalvo M, Gunasekara DB, et al. Self-renewing monolayer of primary colonic or rectal epithelial cells. Cmgh. 2017;4:165–182.e7.
   Google Scholar
• Mayorgas A, Dotti I, Martínez-Picola M, et al. A novel strategy to study the invasive capability of adherent-invasive Escherichia coli by using human primary organoid-derived epithelial monolayers. Front Immunol. 2021;12:1–15.
   Web of Science ®Google Scholar
• Weeber F, Van De Wetering M, Hoogstraat M, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci U S A. 2015;112:13308–13311.
   PubMed Web of Science ®Google Scholar
• Van De Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933–945.
   PubMed Web of Science ®Google Scholar
• Arnauts K, Verstockt B, Ramalho AS, et al. Ex vivo mimicking of inflammation in organoids derived from patients with ulcerative colitis. Gastroenterology. 2020;159:1564–1567.
   PubMed Web of Science ®Google Scholar
• Pauli C, Hopkins BD, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7:462–477.
   PubMed Web of Science ®Google Scholar
• Verissimo CS, Overmeer RM, Ponsioen B, et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. Elife. 2016;5:1–26.
   Web of Science ®Google Scholar
• Dekkers JF, Berkers G, Kruisselbrink E, et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016;8(344):344ra84.
   Web of Science ®Google Scholar
• Vijftigschild LAW, Berkers G, Dekkers JF, et al. 2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis. Eur Respir J. 2016;48:768–779.
   PubMed Web of Science ®Google Scholar
• Schwank G, Koo BK, Sasselli V, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013;13:653–658.
   PubMed Web of Science ®Google Scholar
• Drummond CG, Bolock AM, Ma C, et al. Enteroviruses infect human enteroids and induce antiviral signaling in a cell lineage-specific manner. Proc Natl Acad Sci U S A. 2017;114:1672–1677.
   PubMed Web of Science ®Google Scholar
• Dotti I, Salas A. Potential use of human stem cell-derived intestinal organoids to study inflammatory bowel diseases. Inflamm Bowel Dis. 2018;24:2501–2509.
   PubMed Web of Science ®Google Scholar
• Xu P, Elizalde M, Masclee A, et al. Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohn’s disease. J Mol Med. 2021;99:805–815.
   PubMed Web of Science ®Google Scholar
• d’Aldebert E, Quaranta M, Sébert M, et al. Characterization of human colon organoids from inflammatory bowel disease patients. Front Cell Dev Biol. 2020;8:363.
   Web of Science ®Google Scholar
• Noel G, Baetz NW, Staab JF, et al. A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions. Sci Rep. 2017;7:1–14.
   PubMed Web of Science ®Google Scholar
• Poletti M, Arnauts K, Ferrante M, et al. Organoid-based models to study the role of host-microbiota interactions in IBD. J Crohn’s Colitis. 2020;15:1–14.
   Google Scholar
• Dotti I, Mora-Buch R, Ferrer-Picón E, et al. Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. Gut. 2017;66:2069–2079.
   PubMed Web of Science ®Google Scholar
• Howell KJ, Kraiczy J, Nayak KM, et al. DNA methylation and transcription patterns in intestinal epithelial cells from pediatric patients with inflammatory bowel diseases differentiate disease subtypes and associate with outcome. Gastroenterology. 2018;154:585–598.
   PubMed Web of Science ®Google Scholar
• Nanki K, Fujii M, Shimokawa M, et al. Somatic inflammatory gene mutations in human ulcerative colitis epithelium. Nature. 2020;577:254–259.
   PubMed Web of Science ®Google Scholar
• Spence JR, Mayhew CN, Rankin SA, et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011;470:105–110.
   PubMed Web of Science ®Google Scholar
• Rodansky ES, Johnson LA, Huang S, et al. Intestinal organoids: a model of intestinal fibrosis for evaluating anti-fibrotic drugs. Exp Mol Pathol. 2015;98:346–351.
   PubMed Web of Science ®Google Scholar
• Steiner CA, Rodansky ES, Johnson LA, et al. AXL is a potential target for the treatment of intestinal fibrosis. Inflamm Bowel Dis. 2021;27:303–316.
   PubMed Web of Science ®Google Scholar
• Sarvestani SK, Signs S, Hu B, et al. Induced organoids derived from patients with ulcerative colitis recapitulate colitic reactivity. Nat Commun. 2021;12:1–18.
   PubMed Web of Science ®Google Scholar
• Kasendra M, Tovaglieri A, Sontheimer-Phelps A, et al. Development of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids. Sci Rep. 2018;8:1–14.
   PubMed Web of Science ®Google Scholar
• Beaurivage C, Kanapeckaite A, Loomans C, et al. Development of a human primary gut-on-a-chip to model inflammatory processes. Sci Rep. 2020;10:1–16.
   PubMed Web of Science ®Google Scholar
• Kasendra M, Luc R, Yin J, et al. Duodenum intestine-chip for preclinical drug assessment in a human relevant model. Elife. 2020;9:1–23.
   Web of Science ®Google Scholar
• Nikolaev M, Mitrofanova O, Broguiere N, et al. Homeostatic mini-intestines through scaffold-guided organoid morphogenesis. Nature. 2020;585:574–578.
   PubMed Web of Science ®Google Scholar
• Abraham C, Dulai PS, Vermeire S, et al. Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterology. 2017;152:374–388.e4.
   PubMed Web of Science ®Google Scholar
• Hanžel J, D’Haens GR. Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin Biol Ther. Taylor and Francis Ltd. 2020;20(4):399–406.
   PubMed Web of Science ®Google Scholar
• Bai F, Li GG, Liu Q, et al. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network. J Immunol Res. Hindawi Limited. 2019;2019:2546161.
   Web of Science ®Google Scholar
• Sandborn WJ, Cyrille M, Hansen MB, et al. Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenterology. 2019;156:946–957.e18.
   PubMed Web of Science ®Google Scholar
• Modi NB, Cheng X, Mattheakis L, et al. Single‐ and multiple‐dose pharmacokinetics and pharmacodynamics of pn‐943, a gastrointestinal‐restricted oral peptide antagonist of α4β7, in healthy volunteers. Clin Pharmacol Drug Dev. 2021;2021:cpdd.946.
   Google Scholar
• UEG - United European Gastroenterology [Internet]. [ cited 2021 May 12]. Available from: https://ueg.eu/library/etrolizumab-compared-with-adalimumab-or-placebo-as-induction-therapy-for-ulcerative-colitis-results-from-the-randomized-phase-3-hibiscus-i-ii-trials/235050
   Google Scholar
• Fukase H, Kajioka T, Oikawa I, et al. AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: a randomised controlled trial in healthy male subjects. 2019.
   Google Scholar
• Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015;149:1775–1783.e2.
   PubMed Web of Science ®Google Scholar
• Wang Y, Marier JF, Lavigne J, et al. Population pharmacokinetics and pharmacodynamics of ontamalimab (SHP647), a fully human monoclonal antibody against mucosal addressin cell adhesion molecule-1 (MAdCAM-1), in patients with ulcerative colitis or crohn’s disease. J Clin Pharmacol. 2020;60:903–914.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Sandborn WJ, Danese S, et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:135–144.
   PubMedGoogle Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215–1226.
   PubMed Web of Science ®Google Scholar
• Garrido-Trigo A, Salas A. Molecular structure and function of janus kinases: implications for the development of inhibitors. J Crohn’s Colitis. 2020;14:S713–S724.
   Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
   PubMed Web of Science ®Google Scholar
• Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. Clin Pharmacokinet. 2015;54:859–874.
   PubMed Web of Science ®Google Scholar
• Nader A, Stodtmann S, Friedel A, et al. Pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis, crohn’s disease, ulcerative colitis, or atopic dermatitis: population analyses of phase 1 and 2 clinical trials. J Clin Pharmacol. 2020;60:528–539.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:S0140-6736(21)00666–8.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139–2149.e14.
   PubMed Web of Science ®Google Scholar
• Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62:8973–8995.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Nguyen DD, Beattie DT, et al. Development of gut-selective pan-janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme. J Crohn’s Colitis. 2020;2020:1202–1213.
   Google Scholar
• Pyne NJ, Pyne S. Sphingosine 1-phosphate receptor 1 signaling in mammalian cells. Molecules. MDPI AG. 2016;76(11):1067-1079.
   Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374:1754–1762.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158:550–561.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Chiorean M, Panés J, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohn’s Colitis. 2021;2021:1–10.
   Google Scholar
• Paul G, Khare V, Gasche C. Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest. 2012;42(1):95–109.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Gastroenterology. 2000;119:1461–1472.
   PubMed Web of Science ®Google Scholar
• Fay NC, Muthusamy B-P, Nyugen LP, et al. A novel fusion of IL-10 engineered to traffic across intestinal epithelium to treat colitis. J Immunol. 2020;205:3191-3204.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Wang Y, Lekkerkerker A, et al. Randomized phase I healthy volunteer study of UTTR1147A (IL-22Fc): a potential therapy for epithelial injury. Clin Pharmacol Ther. 2019;105:177–189.
   PubMed Web of Science ®Google Scholar
• Mannon PJ. Expert opinion on biological therapy remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn’s disease. 2011.
   Google Scholar
• Chandan S, Mohan BP, Chandan OC, et al. Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and meta-analysis of clinical trials. Ann Gastroenterol. 2020;33:53–58.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Paramsothy R, Rubin DT, et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J Crohn’s Colitis. 2017;11:1180–1199.
   Google Scholar